<unk> , sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of<unk>  and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. Some evidence also supports use in HCV genotype 3 and 4. It is taken daily by mouth for 8–24 weeks. It is generally well tolerated. Common side effects include muscle pains, headache, nausea, rash, and cough. It is unclear if use in pregnancy is safe for the baby.<unk>  works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B polymerase.<unk>  was approved for medical use in the United States, in the European Union, and in Canada in 2014. It is on the World Health Organization's List of Essential Medicines.
Ledipasvir/sofosbuvir
Atazanavir/ritonavir
Sofosbuvir/velpatasvir
Abacavir/lamivudine
Baloxavir marboxil
Atazanavir/cobicistat
Lamivudine/tenofovir
Fosamprenavir